Clinical Trials Logo
  1. Home
  2. Immune Checkpoint Inhibitor
  3. NCT05385185

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Leptomeningeal Metastasis Clinical Trial

Official title:
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Clinical Trial Summary

immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe

Clinical Trial Description

We will recruit 20 patients with leptomeningeal metastases from lung cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05385185
Study type Interventional
Source Hebei Medical University
Contact hui bu, PhD
Phone 0311-66003711-211
Email buhuimy1@163.com
Status Recruiting
Phase Phase 2
Start date May 1, 2022
Completion date December 3, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT04178343 - Tomotherapy for Leptomeningeal Metastases N/A
Recruiting NCT06399926 - Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Not yet recruiting NCT06441045 - Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI Phase 2
Recruiting NCT04425681 - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Recruiting NCT02803619 - A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis N/A
Recruiting NCT05746754 - Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis N/A
Not yet recruiting NCT04148898 - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis Phase 2
Completed NCT04420598 - DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease Phase 2
Completed NCT02071056 - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
Terminated NCT04729348 - Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Phase 2
Recruiting NCT06304441 - Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer N/A
Not yet recruiting NCT06296745 - Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. Phase 2
Recruiting NCT04778800 - A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) N/A
Not yet recruiting NCT06282874 - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Phase 4
Not yet recruiting NCT04356118 - Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Phase 4
Not yet recruiting NCT04356222 - Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Phase 4
Not yet recruiting NCT06462222 - Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors Phase 1/Phase 2